Liquid Dosage
GEA is a leading specialist in the field of process equipment for liquid processing and metering for the pharmaceutical and biotech industries, including fermentation plant for the manufacture of products such as monoclonal antibodies (mAbs) for diagnostic and therapeutic purposes.
Monoclonal antibodies are known as targeted therapies because they work by targeting specific proteins on the surface of cells. Successfully used to treat cancers, tumors and other serious diseases, mAbs are — compared with other biopharmaceutical products — large proteins that require relatively high administration doses and traditionally necessitate high-volume manufacturing equipment/systems and facilities. GEA offers production systems for monoclonal antibodies that are produced in state-of-the-art stainless steel bioreactors by specific cell cultures.
The cell culture process is done in several steps, starting with 10 L precultures and successively cultivating intermediate batches up to a final production volume of up to 20,000 L. These systems comprise the vessel, with the stirrer as the core element, and peripherals such as temperature control systems, clean-in-place (CIP) components, aeration and deaeration systems, input systems and automated sensors, actuators and the operator interface.
Support processes, such as media preparation and harvest systems are also available from GEA. The process integration of separators and filters for the harvest step is also within GEA’s scope of service. Because of the high sensitivity of the cells and the need for operator and product safety, all GEA system components are designed according to the latest standards and have the highest grade of finish quality.
8 の 4 を表示する
GEA の革新的な CIP コンセプトは、包括的な最高規格を満たしています。当社のエキスパートは、プロセスのあらゆる時点で、製品の安全性を保証しています。どのアップグレードも、現場の個々の条件および顧客の要件に適合し、顕著な節約を実現します。
GEA Hilgeでは、飲料、食品、製薬産業における多岐にわたる感度の高い用途に汎用性の高い遠心ポンプおよび容積型ポンプをご用意しております。
GEA's thorough understanding of the lyophilization process enables them to supply a comprehensive range of products and services, comprising laboratory equipment, pilot plants for research and small-scale production batches, industrial size pharmaceutical production freeze dryers.
かねてから、GEA は医薬品およびバイオテクノロジー用途の超高圧 (VHP) ホモジナイザユニットの基準を確立してきました。当社の供給範囲は、細胞の溶解および粒子径の小型化の用途のためのベンチトップの研究室用機器からパイロット規模および生産用のスキッド搭載システムの社内設計・製造に及びます。
The world's population is growing and with it demand for milk. Dairy is an essential component of many global diets. However, its production can be resource-intensive and impact the environment. GEA’s Christian Müller, Senior Director Sustainability Farm Technologies, sheds light on how technological innovations powered by GEA make milk production more efficient and profitable.